Tags

Type your tag names separated by a space and hit enter

Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism.
Kidney Int. 1988 Jun; 33(6):1160-8.KI

Abstract

The nephrotic syndrome is characterized by proteinuria, hypoalbuminemia, and hypercholesterolemia. Hypertriglyceridemia often is present as well. In this study, the kinetics of plasma lipoproteins were investigated in four patients with nephrotic hyperlipidemia, and repeat studies were carried out in three of these patients during therapy with lovastatin. Before lovastatin therapy, the patients had an extremely delayed catabolism of very low density lipoproteins (VLDL) without evidence of overproduction of lipoproteins in this fraction. Three of four patients had elevated levels of low density lipoprotein (LDL) that were due mainly to increased production rates for LDL. In the three patients treated with lovastatin, the drug therapy lowered plasma concentrations of total cholesterol, triglycerides, VLDL-cholesterol, and LDL-cholesterol, and raised high density lipoprotein (HDL)-cholesterol. Lovastatin therapy decreased VLDL-triglycerides primarily by enhancing their catabolism, and lowered LDL-cholesterol levels mainly by reducing input rates for LDL. Overall, lovastatin appears to be an effective drug for the treatment of hyperlipidemia in the nephrotic syndrome.

Authors+Show Affiliations

Veterans Administration Medical Center, University of Texas Southwestern Medical Center, Dallas.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

3165483

Citation

Vega, G L., and S M. Grundy. "Lovastatin Therapy in Nephrotic Hyperlipidemia: Effects On Lipoprotein Metabolism." Kidney International, vol. 33, no. 6, 1988, pp. 1160-8.
Vega GL, Grundy SM. Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism. Kidney Int. 1988;33(6):1160-8.
Vega, G. L., & Grundy, S. M. (1988). Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism. Kidney International, 33(6), 1160-8.
Vega GL, Grundy SM. Lovastatin Therapy in Nephrotic Hyperlipidemia: Effects On Lipoprotein Metabolism. Kidney Int. 1988;33(6):1160-8. PubMed PMID: 3165483.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism. AU - Vega,G L, AU - Grundy,S M, PY - 1988/6/1/pubmed PY - 1988/6/1/medline PY - 1988/6/1/entrez SP - 1160 EP - 8 JF - Kidney international JO - Kidney Int VL - 33 IS - 6 N2 - The nephrotic syndrome is characterized by proteinuria, hypoalbuminemia, and hypercholesterolemia. Hypertriglyceridemia often is present as well. In this study, the kinetics of plasma lipoproteins were investigated in four patients with nephrotic hyperlipidemia, and repeat studies were carried out in three of these patients during therapy with lovastatin. Before lovastatin therapy, the patients had an extremely delayed catabolism of very low density lipoproteins (VLDL) without evidence of overproduction of lipoproteins in this fraction. Three of four patients had elevated levels of low density lipoprotein (LDL) that were due mainly to increased production rates for LDL. In the three patients treated with lovastatin, the drug therapy lowered plasma concentrations of total cholesterol, triglycerides, VLDL-cholesterol, and LDL-cholesterol, and raised high density lipoprotein (HDL)-cholesterol. Lovastatin therapy decreased VLDL-triglycerides primarily by enhancing their catabolism, and lowered LDL-cholesterol levels mainly by reducing input rates for LDL. Overall, lovastatin appears to be an effective drug for the treatment of hyperlipidemia in the nephrotic syndrome. SN - 0085-2538 UR - https://www.unboundmedicine.com/medline/citation/3165483/Lovastatin_therapy_in_nephrotic_hyperlipidemia:_effects_on_lipoprotein_metabolism_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0085-2538(15)34298-8 DB - PRIME DP - Unbound Medicine ER -